AZ’s Alexion takeover hits a snag, as Ultomiris flunks ALS trial

It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the merger has already had a setback.

Alexion has dropped development of its Ultomiris drug in amyotrophic lateral sclerosis (ALS), chalking up the first clinical failure for the drug since AZ took control.